Expanding Diagnostic Services Inform Diagnostics offers a broad range of pathology and molecular diagnostic services, including dermatopathology, gastrointestinal, hematopathology, and Covid-19 testing. Opportunities exist to expand partnerships with hospitals and clinics seeking comprehensive, state-of-the-art diagnostic solutions.

Technology Integration With a tech stack that includes Azure SQL, Salesforce Marketing Cloud, and advanced lab tools, the company is positioned to leverage modern IT solutions. Selling opportunities may include advanced AI and cloud-based data management tools to enhance laboratory efficiency and data analytics capabilities.

Potential Growth Through Acquisition Following Fulgent Genetics’ acquisition for $170 million, there is potential for further strategic acquisitions or partnerships to grow market share and improve diagnostic offerings, especially in molecular diagnostics and specialty pathology niches.

Market Positioning As a trusted provider serving U.S. clinicians and with modern laboratories in major cities, Inform Diagnostics can be targeted for solutions that improve operational efficiency, compliance, and patient engagement, especially with providers looking to upgrade their diagnostic infrastructure.

Regulatory and Compliance Focus The company’s past issues with billing fraud and False Claims Act cases highlight the importance of compliance solutions. There is a sales opportunity for tools that ensure regulatory adherence, streamline billing practices, and mitigate legal risks.